Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer

(2011) Susan F. Dent et al.   BREAST CANCER RESEARCH AND TREATMENT

Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients

(2010) Dawn L. Hershman et al.   JOURNAL OF CLINICAL ONCOLOGY

Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer

(2009) V. Ziller et al.   ANNALS OF ONCOLOGY

Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy

(2009) Peyman Hadji   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Managing the toxicities of the aromatase inhibitors

(2009) Joanne E Mortimer   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer

(2008) U Güth et al.   BRITISH JOURNAL OF CANCER

Menopausal symptoms and adjuvant therapy-associated adverse events

(2008) P Hadji   ENDOCRINE-RELATED CANCER

Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer

(2008) Ann H. Partridge et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

(2008)   LANCET ONCOLOGY

Predictors of Tamoxifen Discontinuation Among Older Women With Estrogen Receptor–Positive Breast Cancer

(2007) Cynthia Owusu et al.   JOURNAL OF CLINICAL ONCOLOGY